Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Research and Innovation Action · Running

MVC-2G Optimising a Deployable High Efficacy Multi-Stage Vaccine for Plasmodium falciparum Malaria: 2nd Generation Malaria Vaccine Consortium

Coordinator
The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
Runs
8 September 2025 to 7 September 2030
Status
Running
EU funding
€15.0m
Total cost
€15.0m
Partners
9 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101190695

What the project is doing

In the project's own words, from its summary on CORDIS.

The 2nd Generation Malaria Vaccine Consortium (MVC-2G) will build on the programmatic use of the first-generation Plasmodium falciparum vaccine, R21 with Matrix-M™, and accelerate the clinical development of the leading second-generation multi-stage P. falciparum malaria vaccine comprising R21 and two novel blood-stage components, RH5.1 and R78C, all formulated in Matrix-M™. It will achieve this through a multi-disciplinary workplan, underpinned by international cooperation, that will accelerate the future achievement of the United Nations’ Sustainable Development Goal 3 (SDG3) in sub-Saharan African countries.

Its specific objectives are to: 1. Demonstrate safety and superior efficacy against clinical malaria (over R21/MM alone) of the leading second-generation multi-stage vaccine candidate R21+RH5.1+R78C/MM in a Phase 2b trial in 5-17 month old African infants, in a seasonal setting; 2. In parallel, undertake Phase 1b assessment of the second-generation multi-stage vaccine in African infants to define a 3 or 4 dose delivery schedule that is better aligned with EPI and end-user community expectations, aiming for lower cost of goods and to facilitate improved future uptake of a second-generation product; 3.

Demonstrate safety and superior efficacy of the multi-stage vaccine (over R21/MM alone) delivered in an optimised age-based schedule in a multi-site Phase 2b trial in African infants in seasonal and perennial settings; 4. Generate evidence to support use of the multi-stage vaccine in future malaria elimination campaigns by assessment of i) efficacy in adults by CHMI, and ii) safety and immunogenicity in older children; 5.

Support the next-generation of early-career African scientists, across all partners in the Consortium, by growing a South-South network to facilitate hands on clinical and laboratory training; and 6. Undertake early engagement with regulators in partner countries to facilitate translation and future registration of this multi-stage vaccine.

Who is involved

OrganisationCityCountryRole
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomCoordinator
Centre National De Recherche Scientifique Et Technologique*institut De Recherche En Sciences De La SanteOuagadougouBurkina FasoParticipant
European Vaccine Initiative eVHeidelbergGermanyParticipant
Expres2ion Biotechnologies ApsHorsholmDenmarkParticipant
Centre for Malaria and Other Tropical Diseases Care, IlorinIlorinNGParticipant
University of Sierra LeoneFreetownSLParticipant
Institut Pasteur De DakarDakarSNParticipant
The Registered Trustees of the Ifakara Health InstituteDar Es SalaamTZParticipant
London School of Hygiene and Tropical Medicine Royal CharterLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI